Throughout the long history of coexistence between humans and microorganisms, Staphylococcus aureus (SA) has remained a formidable “old adversary”. As a representative Gram‑positive bacterium, it is widely distributed in the natural environment and on human body surfaces. Statistically, SA colonizes the nasal vestibule in approximately 30% of healthy individuals and the skin surface in 20% of healthy people.

When immunity is compromised or the skin barrier is damaged, SA can cause a spectrum of diseases ranging from local purulent infections to severe conditions such as pneumonia, pericarditis, septicemia, and even sepsis.

Of greater concern is the drug‑resistant strain of SA—Methicillin‑resistant Staphylococcus aureus (MRSA)—which has become a major global public health threat. MRSA carries the SCCmec gene cassette. The mecA gene and/or mecC (mecA variant mecA_LGA251) within SCCmec encode modified penicillin‑binding proteins PBP2a or PBP2c, which reduce affinity for methicillin and other β‑lactam antibiotics, leading to resistance, often multidrug resistance.

MRSA is not only common in hospital‑acquired infections but also spreads in community settings, serving as a leading cause of surgical site infections (SSI), bloodstream infections, and pneumonia.

The prevalence of MRSA continues to rise worldwide. According to data from multiple antimicrobial resistance surveillance networks (including CARSS, CHINET, and BRICS), MRSA accounts for a high proportion of Staphylococcus aureus isolates. In high‑risk populations such as surgical patients, dialysis patients, and immunosuppressed individuals, MRSA infection leads to prolonged treatment, increased medical costs, and even higher mortality.

Limitations of Traditional Detection Methods

Bacterial culture has long been the “gold standard” for detecting SA and MRSA. Although highly specific, it is time‑consuming, typically requiring 3–5 days for preliminary identification. Additional waiting is needed for antimicrobial susceptibility testing. This delay not only misses the optimal window for anti‑infective treatment but also increases the risk of nosocomial transmission.

Furthermore, culture requires a high bacterial load in samples and has limited sensitivity, especially in patients already on antibiotics, where false negatives frequently occur. There is thus an urgent clinical need for rapid, accurate, and efficient detection to enable early diagnosis and precise intervention.

Molecular Diagnostics: A Powerful Tool for the New Era

With advances in molecular biology, nucleic acid testing has become the mainstream approach for pathogen detection. Real‑time fluorescent PCR, in particular, is widely used for drug‑resistant bacteria detection due to its high sensitivity, high specificity, and rapid results.

Using specific primers and probes, the assay directly detects gene sequences unique to SA and signature genes of MRSA, enabling molecular identification of SA and MRSA. The entire process can be completed within 1 hour, drastically reducing turnaround time.

Rocgene iFIND Molecular POCT

Only One Manual Step Required

Technical Features

Nucleic Acid Detection Kit for

Staphylococcus aureus and MRSA

Targets: Staphylococcus aureus, mecA, mecC, SCCmec

Sample Type: Skin, tissue, mucus

Storage: Room‑temperature transport

Sensitivity: 500 copies/mL

Time to Result: 60 min

Cartridge Kit

Key Advantages of the iFIND Automated Nucleic Acid Detection Platform

Simple operation: Manual handling < 1 min; results in 60 min.

Higher positivity rate: PCR‑based molecular method significantly improves detection rate.

Multiplex detection: One sample simultaneously identifies SA and MRSA.

60‑min results: No culture or susceptibility waiting time, greatly reducing turnaround.

Treatment optimization: Rapid, accurate results support targeted antimicrobial therapy.

Improved infection control: Proactive screening of high‑risk admissions/transfers and high‑risk wards enables timely isolation and reduces MRSA transmission.

This kit is intended for testing skin, tissue, and mucus samples,

primarily for the following high‑risk populations:

Preoperative patients (cardiac, orthopedic, etc.);

Intensive Care Unit (ICU) patients;

Organ transplant and hematological disease patients;

Dialysis patients;

Other immunocompromised patients or those on long‑term broad‑spectrum antibiotics.

The prevalence and transmission of MRSA pose an ongoing challenge to healthcare systems worldwide. Rapid, accurate etiological diagnosis is critical not only for personalized treatment but also for nosocomial infection control.

Rocgene automated nucleic acid detection reagents provide a highly efficient and reliable clinical solution, supporting early diagnosis, isolation, and treatment of infectious diseases, ultimately improving patient outcomes and healthcare quality.